Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Response dynamics to belumosudil in chronic graft-versus-host disease: Characterizing late responses and organ-specific response expectations from the rockstar study

View Full Paper
Ask AI
Bookmark
Share

Authors

YYYu YaoRJRan Ji

Discussion

Loading...

Member takes

Overview

Clinical trial shows response rates improving over time in patients with chronic graft-versus-host disease, indicating treatment course may require adjustment by organ involvement.

Key Points

  • Belumosudil achieved clinical responses across various organs involved in chronic graft-versus-host disease.
  • Cumulative response rates reached 100% beyond 12 months, with significant variability among organ responses.
  • Analysis from the Phase 2 ROCKstar trial highlighted that complete responses varied by organ system, impacting treatment strategies.
  • These findings emphasize the need for individualized treatment approaches based on organ-specific divergence in response dynamics.

Cite This Study

Yao et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db99https://doi.org/10.1182/blood-2025-6004
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.2025
  2. 2Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety2025
  3. 3ROCK 2 inhibition with belumosudil for the treatment of chronic graft-versus-host disease: a narrative review2025
  4. 4Belumosudil achieves clinical response in chronic graft-<i>versus</i>host disease with varying organ-specific response kinetics: an analysis from the phase II ROCKstar trial2026
  5. 5Investigating belumosudil in children with refractory moderate-to-severe chronic graft-versus-host disease: Design of a phase 1/2 study2025